Nanoscope Therapeutics to Unveil Key Data on Macular Degeneration…

Event summary

Nanoscope Therapeutics will present data on sonpiretigene isteparvovec for macular degeneration at the 26th Euretina Congress on October 4, 2026.
4-year durability data from the RESTORE Phase 2b/3 trial for retinitis pigmentosa will be shared by Benjamin Bakall, MD, PhD, on October 1, 2026.
Samarendra Mohanty, PhD, will deliver a company presentation at the Retina Forum 2026 on September 30, 2026.
Samuel Barone, MD, will participate in a panel on geographic atrophy and intermediate AMD at the Retina Forum 2026 on September 30, 2026.

The big picture

Nanoscope Therapeutics is advancing its optogenetic pipeline with key data presentations at major ophthalmology conferences, highlighting its potential to become a standard of care for retinal degenerative diseases. The company's focus on disease-agnostic therapies and its regulatory progress with MOGENRY® underscore its strategic positioning in a competitive biotech landscape. The breadth of its pipeline, spanning multiple retinal conditions, positions Nanoscope to capture significant market share if clinical and regulatory milestones are met.

What we're watching

Regulatory Milestones: The FDA's acceptance of the BLA for MOGENRY® sets the stage for potential approval, which could position Nanoscope as a leader in optogenetic therapies for retinitis pigmentosa.
Clinical Pipeline Expansion: The initiation of a Phase 2 program for geographic atrophy and other IND-ready programs, including Leber congenital amaurosis, will be critical to watch for Nanoscope's long-term growth strategy.
Market Differentiation: The company's disease-agnostic approach and the durability of its optogenetic therapy could influence its competitive positioning in the retinal degeneration space.